Skip to main
JBIO

JBIO Stock Forecast & Price Target

JBIO Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Jade Biosciences is positioned for success as they continue to progress through the clinical trials for their drug JADE101, with positive initial results and plans for a more convenient dosing schedule. The company's pipeline of other potential treatments also adds to their promising outlook.

Bears say

Jade Biosciences is a clinical-stage biotechnology company with a promising pipeline but lacks upcoming key data and financial projections. While the Phase 1 results for JADE101 are encouraging, it will not be until the Phase 2 JUNIPER study in 2027 that the true potential of this candidate can be seen. Additionally, the company may face challenges in gaining regulatory approval and competition from other companies in the IgA nephropathy space.

JBIO has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aerovate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aerovate Therapeutics Inc (JBIO) Forecast

Analysts have given JBIO a Strong Buy based on their latest research and market trends.

According to 6 analysts, JBIO has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aerovate Therapeutics Inc (JBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.